Horizon Discovery Group plc provided earnings guidance for the year ended December 31, 2017. For the year, the company announced unaudited pre-close period update for the year ended 31 December 2017. The board reports that the group grew strongly in the second half of the year, providing full year results within its guidance range before the impact of foreign exchange. The group expects financial year 2017 revenues to have grown by approximately 51% on a reported basis compared to £24.1 million a year ago, net of approximately £1.3 million foreign exchange headwinds, with growth driven in particular by bioproduction cell line and diagnostic reagent product sales in the United States and China. Notably, Dharmacon product sales have performed well under Horizon management following the acquisition on 1 September 2017. Gross margins are expected to be approximately 60% on a reported basis, in line with previous guidance and significantly ahead of prior year. The group expects that reported EBITDA before exceptional items and discontinued operations for the full year will be in line with the analyst consensus forecast loss of £1.7 million and that its consolidation and ongoing integration of the business will bear further fruit in 2018. The group expects to report a robust year end cash position of approximately £29 million, with positive gross accounts receivable of approximately £11.4 million. Reaffirmed earnings guidance for the second half of the year 2017, the group is expected to report a positive trend towards profitability in the second half of the year with fourth quarter trading expected to have generated positive EBITDA.